Rozzano

• A Phase III, Randomized, Controlled, Global Multicenter Study to Evaluate the Efficacy and Safety of Oral Tinengotinib versus Physician’s Ch … Recruiting
  2023-505660-11-00 5 2024-04-24 Cholangiocarcinoma (LTT, 26.0)
• Study of GS-5290 in Participants With Moderately to Severely Active Ulcerative Colitis Recruiting
  2022-501119-14-01 4 2024-04-16 Ulcerative Colitis
• STUDY OF OP-1250 ADMINSTERED AS MONOTHERAPY AND COMPARED TO STANDARD OF CARE FOR THE TREATMENT OF ER+, HER2– ADVANCED OR METASTATIC BREAST C … Recruiting
  2023-505871-63-00 5 2024-04-08 ER+, HER2- metastatic breast cancer following endocrine and CDK 4/6 in
• An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2) Recruiting
  2023-504031-41-00 5 2024-03-25 ER+/HER2- Early Breast Cancer
• ​​Lomustine with or without a second round of brain radiation for the reappearance of glioblastoma Recruiting
  2023-505267-36-00 5 2024-03-15 Glioblastoma
• A Master rollover study to provide continued access to, and assess, long term safety of the study drugs. Recruiting
  2023-506330-73-00 5 2024-03-13 Advanced (unresectable or metastatic) human epidermal growth receptor
• A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Efruxifermin in Subjects with Non-Cirrho … Recruiting
  2023-505141-48-00 5 2024-03-07 Fibrosis
• RECOVERY Recruiting
  2023-507441-29-00 5 2024-02-29 Pneumonia
• Adjuvant TRastuzumab deruxtecan plus fluoropyrimidine versus standard chemotherapy In HER2-positive gastric or gastroesophageal cancer patie … Recruiting
  2023-506662-31-00 4 2024-02-28 Gastric or gastroesophageal cancer
• Anticoagulation for Stroke Prevention In patients with Recent Episodes of Atrial Fibrillation occurring transiently with stress Recruiting
  2023-509142-35-00 6 2024-01-29 Atrial fibrillation after stress (e.g., noncardiac surgery or acute me
• A study to Evaluate Efficacy and Safety of Giredestrant Compared with Fulvestrant (plus a CDK4/6 inhibitor), in Participants with ER+ HER2-N … Recruiting
  2022-502980-39-00 5 2024-01-25 Estrogen receptor (ER)-positive, HER2-negative advanced breast cancer
• A Multicenter, Open-Label, Dose-Finding Clinical Trial to Assess the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Efficacy of RV … Recruiting
  2023-505911-19-00 4 2024-01-05 Acute Myeloid Leukemia
• Watch-and-wait strategy to initiate Dostarlimab-based Immunotherapy in localized deficient mismatch repair (dMMR) and/or microsatellite inst … Recruiting
  2023-506102-39-00 4 2023-12-18 metastatic gastric cancer
• Prophylaxis Study of Marstacimab in Pediatric Hemophilia Participants With or Without Inhibitors Recruiting
  2022-500495-65-00 5 2023-12-06 Haemophilia
• A Phase 1, Open-Label, Multicenter Study of INCA033890 in Participants with Advanced or Metastatic Solid Tumors Recruiting
  2022-502456-31-00 1 2023-11-30 Advanced or metastatic solid tumors
• FOENIX-CCA4 Recruiting
  2023-503665-39-00 4 2023-11-14 Advanced cholangiocarcinoma
• A phase II/III randomized clinical trial of CisPlatin plUs Gemcitabine and Nabpaclitaxel (GAP) as pReoperative chemotherapy versus immediate … Recruiting
  2023-503295-25-00 10 2023-10-31 Resectable biliary tract cancers
• Nuwiq for Perioperative management Of patients With haemophilia A on Emicizumab Regular prophylaxis study (NuPOWER) Recruiting
  2022-502060-21-00 6 2023-10-19 Haemophilia A
• The 3TR Molecular Pathobiology-Driven Precision Therapy in RA (3TR Precis-The-RA) study Recruiting
  2022-502021-18-00 6 2023-10-12 Rheumatoid Arthritis
• A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of NXT007 in Persons with Severe or Moderate … Recruiting
  2023-503906-35-00 9 2023-10-11 Severe or Moderate Hemophilia A with or without factor VIII inhibitors
• A study to assess the long-term safety and efficacy of a subcutaneous formulation of efgartigimod in adults with active idiopathic inflammat … Recruiting
  2022-502851-79-00 5 2023-09-20 Active Idiopathic Inflammatory Myopathy (IIM)
• Study to Check the Safety of Fazirsiran and Learn if Fazirsiran Can Help People With Liver Disease and Scarring (Fibrosis) Due to an Abnorma … Recruiting
  2022-501943-34-00 5 2023-06-27 Alpha-1 Antitrypsin Deficiency-Associated Liver Disease
• Window-of-opportunity umbrella platform trial of short-course pre-operative targeted treatments in patients with molecularly selected and re … Recruiting
  2022-501308-90-00 4 2023-05-24 Molecularly selected and resectable primary colorectal cancer
• The ACTION Study: ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy Recruiting
  2022-502051-56-00 5 2023-04-28 H3 K27M-mutant diffuse glioma

Showing 313–336 of 692 trials